BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, February 21, 2026
Home » Authors » Brady Huggett

Articles by Brady Huggett

ImClone Says FDA Might Accept Erbitux BLA With No New Trials

Feb. 28, 2002
By Brady Huggett
ImClone Systems Inc., after being dragged to scandalous depths not often seen in the biotechnology sector, bobbed to the surface Wednesday following its meeting with the FDA concerning the cancer drug Erbitux. (BioWorld Today)
Read More

Biotech Products For Psoriasis Showing Encouraging Results

Feb. 26, 2002
By Brady Huggett
Although there remains no cure for psoriasis, presenters at the 60th annual meeting of the American Academy of Dermatology in New Orleans managed, at the very least, to provide hope for those burdened with the affliction. (BioWorld Today)
Read More

Biotech Products For Psoriasis Showing Encouraging Results

Feb. 26, 2002
By Brady Huggett
Although there remains no cure for psoriasis, presenters at the 60th annual meeting of the American Academy of Dermatology in New Orleans managed, at the very least, to provide hope for those burdened with the affliction. (BioWorld Today)
Read More

Immunex’s Enbrel Performs Well In Phase II Psoriasis Trial

Feb. 25, 2002
By Brady Huggett

Immunex’s Enbrel Performs Well In Phase II Psoriasis Trial

Feb. 25, 2002
By Brady Huggett

Orchid Raises $23M Through Public Offering Of 8M Shares

Feb. 22, 2002
By Brady Huggett

Orchid Raises $23M Through Public Offering Of 8M Shares

Feb. 22, 2002
By Brady Huggett

IDEC Gains Zevalin Approval For Non-Hodgkin’s Lymphoma

Feb. 21, 2002
By Brady Huggett
IDEC Pharmaceuticals Corp. received FDA approval of Zevalin to treat non-Hodgkin’s lymphoma and is poised to introduce the first radioimmunotherapy to the United States. (BioWorld Today)
Read More

Avant Dropping TP10 Following Phase II Failure; Stock Tumbles

Feb. 21, 2002
By Brady Huggett

IDEC Gains Zevalin Approval For Non-Hodgkin’s Lymphoma

Feb. 21, 2002
By Brady Huggett
IDEC Pharmaceuticals Corp. received FDA approval of Zevalin to treat non-Hodgkin’s lymphoma and is poised to introduce the first radioimmunotherapy to the United States. (BioWorld Today)
Read More
Previous 1 2 … 66 67 68 69 70 71 72 73 74 75 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

    BioWorld Science
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • Illustration of head with maze that is missing parts

    Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

    BioWorld Science
    Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
  • Illustration of brain and antibodies

    VST Bio’s VB-001 is neuroprotector after stroke

    BioWorld Science
    At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing